Tanshinone IIA can inhibit human pancreatic carcinoma BxPC3 cells through decreasing the protein expressions of IGFR, EGFR, VEGFR and blocking both Ras/Raf/MEK/ERK and Ras/PI3K/AKT/mTOR pathway in vitro and in vivo

被引：0
|
作者：
Su, C. C. [1 ]
机构：
[1] Changua Christian Hosp, Changhua, Taiwan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-021
引用
收藏
页码：7 / 7
页数：1
相关论文
共 29 条
  • [1] Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo
    Su, Chin-Cheng
    Chiu, Tsung-Lang
    ONCOLOGY REPORTS, 2016, 36 (02) : 1173 - 1179
  • [2] Tanshinone IIA can inhibit MiaPaCa-2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways
    Su, Chin-Cheng
    ONCOLOGY REPORTS, 2018, 40 (05) : 3102 - 3111
  • [3] Tanshinone IIA inhibits gastric carcinoma AGS cells by decreasing the protein expression of VEGFR and blocking Ras/Raf/MEK/ERK pathway
    Su, Chin-Cheng
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 41 (04) : 2389 - 2396
  • [4] Sann-Joong-Kuey-Jian-Tang can inhibit human breast cancer cells through dural-blocking both the Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR pathways
    Su, Chin Cheng
    CANCER RESEARCH, 2016, 76
  • [5] Tanshinone IIA can decrease growth factor receptors expression and dural-block both Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR pathways to inhibit human breast cancer BT-20 cells
    Su, Chin Cheng
    CANCER RESEARCH, 2017, 77
  • [6] PI-103 and Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo by Blocking Ras/Raf/MAPK and PI3K/AKT/mTOR Pathways
    Gedaly, Roberto
    Angulo, Paul
    Hundley, Jonathan
    Daily, Michael F.
    Chen, Changguo
    Koch, Alvaro
    Evers, B. Mark
    LIVER TRANSPLANTATION, 2011, 17 (06) : S87 - S87
  • [7] Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
    Butler, Dominika E.
    Marlein, Christopher
    Walker, Hannah F.
    Frame, Fiona M.
    Mann, Vincent M.
    Simms, Matthew S.
    Davies, Barry R.
    Collins, Anne T.
    Maitland, Norman J.
    ONCOTARGET, 2017, 8 (34) : 56698 - 56713
  • [8] Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
    Chappell, William H.
    Steelman, Linda S.
    Long, Jacquelyn M.
    Kempf, Ruth C.
    Abrams, Stephen L.
    Franklin, Richard A.
    Baesecke, Joerg
    Stivala, Franca
    Donia, Marco
    Fagone, Paolo
    Malaponte, Graziella
    Mazzarino, Maria C.
    Nicoletti, Ferdinando
    Libra, Massimo
    Maksimovic-Ivanic, Danijela
    Mijatovic, Sanja
    Montalto, Giuseppe
    Cervello, Melchiorre
    Laidler, Piotr
    Milella, Michele
    Tafuri, Agostino
    Bonati, Antonio
    Evangelisti, Camilla
    Cocco, Lucio
    Martelli, Alberto M.
    McCubrey, James A.
    ONCOTARGET, 2011, 2 (03) : 135 - 164
  • [9] PI-103 and Sorafenib Inhibit Hepatocellular Carcinoma Cell Proliferation by Blocking Ras/Raf/MAPK and PI3K/AKT/mTOR Pathways
    Gedaly, Roberto
    Angulo, Paul
    Hundley, Jonathan
    Daily, Michael F.
    Chen, Changguo
    Koch, Alvaro
    Evers, B. Mark
    ANTICANCER RESEARCH, 2010, 30 (12) : 4951 - 4958
  • [10] Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways
    Yu Wang
    Hao Nie
    Xin Zhao
    Yong Qin
    Xingguo Gong
    BMC Cancer, 16
123